Showing results (421-430 of 435) with videos related to

Sort By:
Pageof 44
Bulletin Du Cancer. Radiotherapie : Journal De La Societe Francaise Du Cancer : Organe De La Societe Francaise De Radiotherapie Oncologique|January 1, 1996
[Iridium 192 brachytherapy of supra-tentorial high grade glioma recurring in irradiated areas: technique and preliminary results of the Pitié-Salpêtrière hospital group]G Boisserie, P Cornu, D Dormont, et al.
Bulletin Du Cancer|September 8, 1999
[First treatment for brain metastases by stereotactic radiosurgery]L Feuvret, I Germain, P Cornu, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 28, 1998
[Importance of radiotherapy in stereotactic conditions (radiosurgery) in brain metastasis: experience and results of the Hôpital Pitié-Salpêtrière Group]L Feuvret, I Germain, P Cornu, et al.
BMC Medical Education|January 17, 2018
Choosing a career in oncology: results of a nationwide cross-sectional studyJ C Faivre, J E Bibault, A Bellesoeur, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 9, 2022
Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancerJ Trédaniel, F Barlési, C Le Péchoux, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|June 12, 2024
[Informed consent in radiotherapy care]C Sire, A Ducteil, J-L Lagrange, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 17, 2016
T Cells Promote Bronchial Epithelial Cell Secretion of Matrix Metalloproteinase-9 via a C-C Chemokine Receptor Type 2 Pathway: Implications for Chronic Lung Allograft DysfunctionM Pain, P-J Royer, J Loy, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2004
Induction treatment before surgery for non-small cell lung cancerW E Eberhardt, K S Albain, H Pass, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
ESMO Open|June 4, 2024
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RA R Filippi, J Bar, C Chouaid, et al.
Pageof 44